2025
The Implications of Oxygen-Dependent Chronic Obstructive Pulmonary Disease on Sac Growth and Mortality Following Endovascular Aneurysm Repair
Bellamkonda K, Suckow B, Columbo J, Upchurch G, Jacobs B, Ochoa Chaar C, Scully R, Goodney P, Scali S, Stone D. The Implications of Oxygen-Dependent Chronic Obstructive Pulmonary Disease on Sac Growth and Mortality Following Endovascular Aneurysm Repair. Annals Of Vascular Surgery 2025, 115: 98-106. PMID: 40081526, DOI: 10.1016/j.avsg.2025.02.019.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseEndovascular AAA repairObstructive pulmonary diseaseSac growthImpact of chronic obstructive pulmonary diseaseOxygen-dependent chronic obstructive pulmonary diseaseEffect of COPD severityCox proportional hazards regressionElective endovascular AAA repairAAA-related mortalityPulmonary diseaseChronic obstructive pulmonary disease severityChronic obstructive pulmonary disease patientsLimited life expectancyIncreased reintervention rateAbdominal aortic aneurysm (AAAEndovascular aneurysm repairElevated mortality ratesPredictors of mortalityPrimary exposureHazards regressionInclusion criteriaIncreased reinterventionsLogistic regressionPost-EVAREarly Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC
Metersky M, Losier A, Fraulino D, Warnock T, Varley C, Le A, Winthrop K, McArdle J, Shakir S, Khare R. Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2025, 31: 507-515. PMID: 40023800, PMCID: PMC11878316, DOI: 10.3201/eid3103.240608.Peer-Reviewed Original ResearchConceptsNontuberculous mycobacterial pulmonary diseaseMycobacterial pulmonary diseaseAmerican Thoracic Society/Infectious Diseases Society of America criteriaAntimicrobial drug susceptibility testingPulmonary diseaseDrug susceptibility testingRefractory to treatmentClinically significant causeClarithromycin susceptibilitySusceptibility testingConnecticut patientsRespiratory secretionsPatientsNo symptomsOptimum treatmentSignificant causeInfectionHuman casesDiseaseTreatmentCDCClarithromycinCasesClinicM. nebraskense
2024
Severe Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults
Legakis L, Nguyen D, Bandaranayake T. Severe Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults. Infectious Diseases In Clinical Practice 2024, 32: e1412. DOI: 10.1097/ipc.0000000000001412.Peer-Reviewed Original ResearchSevere adenoviral infectionAdenoviral infectionImmunocompetent patientsClinical outcomesSmoking historyPulmonary diseaseRisk factorsSevere diseaseAdenoviral respiratory infectionUpper respiratory tract infectionRespiratory viral panelAbsence of feverAdult immunocompetent patientsExtracorporeal membrane oxygenationRespiratory tract infectionsSevere clinical outcomesChronic obstructive pulmonary diseasePresence of coinfectionObstructive pulmonary diseasePotential risk factorsCritical careImmunocompetent adultsImmunocompromised patientsImmunocompetent hostsTract infectionsChitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPα- and CD24-Siglec10-Mediated Phagocytosis.
Ma B, Kamle S, Sadanaga T, Lee C, Lee J, Yee D, Zhu Z, Silverman E, DeMeo D, Choi A, Lee C, Elias J. Chitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPα- and CD24-Siglec10-Mediated Phagocytosis. The Journal Of Immunology 2024, 213: 1279-1291. PMID: 39291933, DOI: 10.4049/jimmunol.2400035.Peer-Reviewed Original ResearchImmune checkpoint moleculesChronic obstructive pulmonary diseaseInhibit adaptive immune responsesAdaptive immune responsesInnate immune responseImmune responseInhibition of innate immune responsesInhibits T cell costimulationGeneration of adaptive immune responsesMacrophage phagocytosisInhibit innate immune responsesChitinase 3-like 1T cell costimulationEpithelial cell deathObstructive pulmonary diseaseCheckpoint moleculesPoor prognosisLung injuryInhibit macrophagesPulmonary diseaseCHI3L1Inflammation pathwaysCancerSHP-2 phosphataseCell deathPhylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
Cudahy P, Liu P, Warren J, Sobkowiak B, Yang C, Ioerger T, Wu C, Lu P, Wang J, Chang H, Huang H, Cohen T, Lin H. Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1562-1570. PMID: 39043390, PMCID: PMC11286038, DOI: 10.3201/eid3008.240021.Peer-Reviewed Original ResearchConceptsM. kansasii lung diseaseM. kansasii pulmonary diseasePulmonary diseaseM. kansasii isolatesSputum mycobacterial cultureWhole-genome sequencingEvaluate risk factorsPhylogeographic analysisAge of participantsGenetic relatednessEnvironmental acquisitionLung diseaseMycobacterial cultureOdds ratioRisk factorsM. kansasiiPatientsDiseasePlantsEnvironmental transmissionIsolatesPark plantingsCDCRiskAnesthesia Techniques for Vitreoretinal Surgery in the United States: A Report from the Multicenter Perioperative Outcomes Group Research Consortium
Chauhan M, SOLIMAN M, Pace N, Mathis M, Schonberger R, Sallam A, Group M. Anesthesia Techniques for Vitreoretinal Surgery in the United States: A Report from the Multicenter Perioperative Outcomes Group Research Consortium. American Journal Of Ophthalmology 2024, 267: 30-40. PMID: 38871268, DOI: 10.1016/j.ajo.2024.06.010.Peer-Reviewed Original ResearchMonitored anesthesia careVR surgeryMulticenter Perioperative Outcomes GroupGeneral anesthesiaAmerican Society of Anesthesiologists (ASAHistory of drug abuseChronic pulmonary diseaseType of anesthesiaMonitored anesthesia care casesAlcohol abuse disordersMultivariate mixed-effects modelRandom-effects modelRetinal detachmentSB surgeryVitreoretinal surgeryYounger patientsAnesthesia useSurgery casesOutcome groupAnesthesia techniquesPrimary outcomeSurgeryLiver diseaseSecondary outcomesPulmonary diseaseDCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, Bozkurt B, Budoff M, Butler J, Cherney D, DeFronzo R, Del Prato S, Eckel R, Filippatos G, Fonarow G, Fonseca V, Garvey W, Giorgino F, Grant P, Green J, Greene S, Groop P, Grunberger G, Jastreboff A, Jellinger P, Khunti K, Klein S, Kosiborod M, Kushner P, Leiter L, Lepor N, Mantzoros C, Mathieu C, Mende C, Michos E, Morales J, Plutzky J, Pratley R, Ray K, Rossing P, Sattar N, Schwarz P, Standl E, Steg P, Tokgözoğlu L, Tuomilehto J, Umpierrez G, Valensi P, Weir M, Wilding J, Wright E. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism 2024, 159: 155931. PMID: 38852020, DOI: 10.1016/j.metabol.2024.155931.Peer-Reviewed Original ResearchChronic kidney diseaseAtherosclerotic cardiovascular diseaseHeart failureMetabolic diseasesCardiorenal risk factorsEssentials of managementPractice recommendationsType 2 diabetesImprove patient outcomesVolunteer task forcePrimary care physiciansMetabolic comorbiditiesMultispecialty consensusOutcome trialsManagement of personsKidney diseaseLiver diseasePathophysiological pathwaysPulmonary diseaseRisk factorsSteatotic liver diseaseManagement of diabetesCardiovascular diseasePatient outcomesCare physiciansLongitudinal multicompartment characterization of host-microbiota interactions in patients with acute respiratory failure
Kitsios G, Sayed K, Fitch A, Yang H, Britton N, Shah F, Bain W, Evankovich J, Qin S, Wang X, Li K, Patel A, Zhang Y, Radder J, Dela Cruz C, Okin D, Huang C, Van Tyne D, Benos P, Methé B, Lai P, Morris A, McVerry B. Longitudinal multicompartment characterization of host-microbiota interactions in patients with acute respiratory failure. Nature Communications 2024, 15: 4708. PMID: 38830853, PMCID: PMC11148165, DOI: 10.1038/s41467-024-48819-8.Peer-Reviewed Original ResearchConceptsAcute respiratory failureRespiratory failureCohort of COVID-19 patientsLung microbiotaMechanically ventilated patientsChronic obstructive pulmonary diseaseIllumina amplicon sequencingDNA sequencing technologiesHost-microbiota interactionsObstructive pulmonary diseaseCOVID-19 patientsAssociated with specific patternsAntibiotic exposureClinical factorsNanopore metagenomicsPredicting survivalPrecision medicine interventionsPrognostic biomarkerSequencing technologiesAmplicon sequencingPulmonary diseaseGut microbiotaCritical illnessMicrobial diversityHuman microbiomeImmunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection
Cinco I, Napier E, Rhoades N, Davies M, Allison D, Kohama S, Bermudez L, Winthrop K, Fuss C, Spindel E, Messaoudi I. Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection. MBio 2024, 15: e00829-24. PMID: 38771046, PMCID: PMC11237422, DOI: 10.1128/mbio.00829-24.Peer-Reviewed Original ResearchConceptsNTM pulmonary diseaseIncreased disease severityNontuberculous mycobacteriaDisease severityBacterial DNAAged animalsAntigen-specific T cellsPulmonary diseaseAssociated with increased disease severityDysregulated macrophage responsePersistence of bacterial DNALack of animal modelsRhesus macaquesSingle-cell RNA sequencingNontuberculous mycobacterial infectionsImmune cell infiltrationRhesus macaque modelBacterial loadAged rhesus macaquesTesting novel therapeuticsRight caudal lobeLower respiratory microbiomeYears of ageMAH infectionMicrobial communitiesEosinophilia is a favorable marker for pneumonia in chronic obstructive pulmonary disease
Gu K, Jung J, Kang M, Kim D, Choi H, Cho Y, Jang S, Lee C, Oh Y, Park J, Kim J. Eosinophilia is a favorable marker for pneumonia in chronic obstructive pulmonary disease. Tuberculosis And Respiratory Diseases 2024, 87: 465-472. PMID: 38710525, PMCID: PMC11468446, DOI: 10.4046/trd.2023.0174.Peer-Reviewed Original ResearchCommunity-acquired pneumoniaChronic obstructive pulmonary diseaseCost of medical careObstructive pulmonary diseaseMedical careDuration of antibiotic treatmentReduced C-reactive protein levelsPneumonia Severity Index scorePulmonary diseaseCommunity-acquired pneumonia patientsC-reactive protein levelsHealth-care consumptionCohort study dataSeverity index scoreSeverity of pneumoniaPost hoc analysisClinical characteristicsAntibiotic treatmentFewer episodesEosinophiliaMulti-centerPatientsPneumonia patientsPneumoniaEosinophilic patientsSingle-cell RNA-seq analysis of cell-cell communications in human lung reveals a novel role of VEGF-D in acute lung injury
Yuan Y, Sharma L, Tang W, Raredon M, Ahangari F, Khoury J, Wu D, Niklason L, Kaminski N. Single-cell RNA-seq analysis of cell-cell communications in human lung reveals a novel role of VEGF-D in acute lung injury. Physiology 2024, 39: 1314. DOI: 10.1152/physiol.2024.39.s1.1314.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisAcute lung injuryChronic obstructive pulmonary diseaseAcute respiratory distress syndromeAnalysis of cell-cell communicationVEGF-DMicrovascular nicheSingle-cell RNA-seqLung injury modelSingle-cell RNA-seq analysisLung injuryCell-cell communicationLigand-receptor pairsLPS-induced lung injury modelRNA-seqAdjacent cell typesPulmonary diseaseInjury modelHuman lung endothelial cellsBarrier functionImmune cell infiltrationTumor necrosis factor-aRespiratory distress syndromeLung vascular integrityGene expressionA Pilot Study Utilizing Wearable Samplers to Assess Personal Chemical Exposure Profile of Patients With Chronic Obstructive Pulmonary Disease
Huston J, Valle G, Stewart J, Lin E, Zhou J, Liu S, Rochester C, Pollitt K, Dela Cruz C. A Pilot Study Utilizing Wearable Samplers to Assess Personal Chemical Exposure Profile of Patients With Chronic Obstructive Pulmonary Disease. 2024, a3094-a3094. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3094.Peer-Reviewed Original ResearchRacial Differences in 1-Year Mortality after Hospitalization for Chronic Obstructive Pulmonary Disease in the United States.
Jain S, Priya A, Pekow P, Spitzer K, Walkey A, Opara I, Krumholz H, Lindenauer P. Racial Differences in 1-Year Mortality after Hospitalization for Chronic Obstructive Pulmonary Disease in the United States. Annals Of The American Thoracic Society 2024, 21: 585-594. PMID: 37943953, PMCID: PMC10995557, DOI: 10.1513/annalsats.202304-359oc.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseChronic obstructive pulmonary disease hospitalizationsObstructive pulmonary diseaseMedicare beneficiariesWhite racePulmonary diseaseChronic obstructive pulmonary disease exacerbationsChronic obstructive pulmonary disease patientsObstructive pulmonary disease exacerbationsObstructive pulmonary disease patientsHospital-level clusteringPulmonary disease exacerbationsRetrospective cohort studyPulmonary disease patientsCox regression modelIndividual socioeconomic statusDisease exacerbationPulmonary rehabilitationCohort studyDischarge dispositionOverall mortalityIllness severityHospitalized populationCare factorsDisease patientsLung infections due to emerging fungal pathogens
Roman F, Pischel L, Azar M. Lung infections due to emerging fungal pathogens. Current Opinion In Pulmonary Medicine 2024, 30: 258-265. PMID: 38411158, DOI: 10.1097/mcp.0000000000001059.Peer-Reviewed Original ResearchConceptsEndemic mycosesManagement of pulmonary infectionsFungal pathogensPathogenic fungiAntifungal prophylaxisBlastomyces speciesFungal infectionsFungal organismsAspergillus moldsEnvironmental changesImmunocompromised hostsPulmonary infectionTherapeutic challengeLung infectionMycosesClinical evidenceClinical managementIncreased incidencePulmonary diseaseEnlarged poolDisease burdenInfectionLomentosporaScedosporiumDiagnostic capabilitiesFemale reproductive histories and the risk of chronic obstructive pulmonary disease
Liang C, Chung H, Dobson A, Sandin S, Weiderpass E, Mishra G. Female reproductive histories and the risk of chronic obstructive pulmonary disease. Thorax 2024, 79: 508-514. PMID: 38350732, DOI: 10.1136/thorax-2023-220388.Peer-Reviewed Original ResearchConceptsRisk of chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseFemale reproductive factorsReproductive factorsObstructive pulmonary diseaseNatural menopauseBirth yearIncreased risk of COPDPulmonary diseaseBody mass indexDevelopment of chronic obstructive pulmonary diseaseEducation levelCox regression modelsMass indexReproductive historyIncreased riskCohort differencesStillbirthRegression modelsFemale reproductive historyMenarcheMedian follow-upWomenFemale hormonal environmentCohortComparing the rate of immunotherapy treatment change due to toxicity by sex
Chua K, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi S, Liu H, Tarhini A, Gatti‐Mays M, Gaughan E, Hu‐Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer E. Comparing the rate of immunotherapy treatment change due to toxicity by sex. Cancer Reports 2024, 7: e1932. PMID: 38189893, PMCID: PMC10849926, DOI: 10.1002/cnr2.1932.Peer-Reviewed Original ResearchConceptsImmuno-oncology therapiesChronic obstructive pulmonary diseaseTreatment discontinuation rateDiscontinuation ratesNo significant differenceImmune-related adverse eventsTreatment due to toxicityTreatment changesTreatment-related toxicityPatients changed treatmentSignificant differenceFrequent treatment changesAssociated with chronic obstructive pulmonary diseaseMultivariate logistic regressionObstructive pulmonary diseaseChi-square testState Cancer CenterPrimary endpointAdverse eventsIO treatmentAutoimmune diseasesCancer CenterPulmonary diseasePatientsCancer typesSpatial Transcriptomics Resolve an Emphysema-Specific Lymphoid Follicle B Cell Signature in Chronic Obstructive Pulmonary Disease
Rojas-Quintero J, Ochsner S, New F, Divakar P, Yang C, Wu T, Robinson J, Chandrashekar D, Banovich N, Rosas I, Sauler M, Kheradmand F, Gaggar A, Margaroli C, San Jose Estepar R, McKenna N, Polverino F. Spatial Transcriptomics Resolve an Emphysema-Specific Lymphoid Follicle B Cell Signature in Chronic Obstructive Pulmonary Disease. American Journal Of Respiratory And Critical Care Medicine 2024, 209: 48-58. PMID: 37934672, PMCID: PMC10870877, DOI: 10.1164/rccm.202303-0507le.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseB cell activationObstructive pulmonary diseaseLymphoid folliclesCell activationPulmonary diseaseGOLD 1Chronic Obstructive Lung Disease (GOLD) 1Chronic B-cell activationB cell signaturesDegree of emphysemaB cell marker genesB cell maturationSevere emphysemaAntiinflammatory profileEmphysema measurementsTomographic scanLung sectionsAntigen presentationGOLD 3Centrilobular emphysemaImmune componentsEmphysema pathogenesisEmphysemaLung samples"In their own words": delineating the contours of dyspnea invisibility in patients with advanced chronic obstructive pulmonary disease from quantitative discourse analysis
Dedonder J, Gelgon C, Guerder A, Nion N, Lavault S, Morélot-Panzini C, Gonzalez-Bermejo J, Benoit L, Similowski T, Serresse L. "In their own words": delineating the contours of dyspnea invisibility in patients with advanced chronic obstructive pulmonary disease from quantitative discourse analysis. Respiratory Research 2024, 25: 21. PMID: 38178139, PMCID: PMC10768212, DOI: 10.1186/s12931-023-02655-4.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseasePulmonary diseaseAdvanced chronic obstructive pulmonary diseaseChronic respiratory disease patientsRespiratory disease patientsPersistent dyspneaCOPD patientsDisease patientsMaximal treatmentPatient concernsCausative abnormalityInterpretative phenomenological analysisPatientsDaily limitationsDiseaseBasic activitiesDistressing experiencePatients' discourseNovel informationBackgroundDyspneaDyspneaExacerbationHospitalAbnormalities
2023
The Utilization of Protamine during Peripheral Vascular Interventions in the VQI
Ali S, Shebl F, Aboian E, Strosberg D, Fischer U, Cardella J, Guzman R, Ochoa Chaar C. The Utilization of Protamine during Peripheral Vascular Interventions in the VQI. Annals Of Vascular Surgery 2023, 101: 72-79. PMID: 38110083, DOI: 10.1016/j.avsg.2023.10.019.Peer-Reviewed Original ResearchPeripheral vascular interventionsAdjusted rate ratiosProtamine useCardiac complicationsPropensity matchingVascular interventionsChronic obstructive pulmonary diseasePropensity scoreCharacteristics of patientsPeripheral arterial diseaseCongestive heart failureObstructive pulmonary diseaseMultivariable Poisson regressionUse of protamineSignificant differencesMedical comorbiditiesP2Y12 inhibitorsPerioperative bleedingPerioperative medicationsPerioperative outcomesDistal embolizationPatient comorbiditiesCarotid surgeryHeart failurePulmonary diseaseSpatial Transcriptomics Resolve an Emphysema-specific Lymphoid Follicle B Cell Signature in COPD.
Rojas-Quintero J, Ochsner S, New F, Divakar P, Yang C, Wu T, Robinson J, Shimoga Chandrashekar D, Banovich N, Rosas I, Sauler M, Kheradmand F, Gaggar A, Margaroli C, San Jose Estepar R, McKenna N, Polverino F. Spatial Transcriptomics Resolve an Emphysema-specific Lymphoid Follicle B Cell Signature in COPD. American Journal Of Respiratory And Critical Care Medicine 2023 PMID: 38064378, DOI: 10.1164/rccm.202303-0507oc.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseB cell activationLymphoid folliclesCOPD patientsGOLD 1Cell activationChronic B-cell activationObstructive pulmonary diseaseB cell signaturesAnti-inflammatory profileChest CT scanDegree of emphysemaB cell marker genesB cell maturationSevere emphysemaPulmonary diseaseEmphysema measurementsLung sectionsAntigen presentationGOLD 3Centrilobular emphysemaCT scanImmune componentsEmphysema pathogenesisEmphysema
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply